Skip to main content

Table 2 Isolated cardiomyocyte contractile measurements

From: Adverse transverse-tubule remodeling in a rat model of heart failure is attenuated with low-dose triiodothyronine treatment

  Sham MI + Veh MI + T3
Maximum Shortening Velocity (μm/s) 3.513 ± 0.808 3.125 ± 0.726 3.703 ± 1.213
Maximum Relengthening Velocity (μm/s) 2.299 ± 0.837 1.593 ± 0.325 2.984 ± 1.410#
Time at Maximum Relengthening Velocity (s) 0.248 ± 0.048 0.314 ± 0.019* 0.233 ± 0.037#
Peak Height as Percent of Baseline 11.17 ± 1.97 11.70 ± 1.68 12.11 ± 2.96
Time at % from Baseline to Peak Shortening (s)     
50% 0.049 ± 0.006 0.053 ± 0.005 0.054 ± 0.009
90% 0.109 ± 0.014 0.130 ± 0.006 0.105 ± 0.020#
Time at Peak Shortening (s) 0.165 ± 0.024 0.197 ± 0.011* 0.161 ± 0.021#
Time at % from Peak Shortening to Full Relengthening (s)     
50% 0.258 ± 0.050 0.326 ± 0.018* 0.261 ± 0.071#
90% 0.353 ± 0.071 0.443 ± 0.024* 0.324 ± 0.071#
Tau (exponential decay time constant) (s) 0.048 ± 0.019 0.067 ± 0.008 0.045 ± 0.021#
Area Under Curve of Relengthening Phase 0.021 ± 0.006 0.029 ± 0.004* 0.020 ± 0.005#
  1. Values are mean ± SD. MI, myocardial infarction; Veh, vehicle; T3, triiodothyronine. Tau is exponential decay time constant of the sarcomere relengthening phase. Sham, n = 7; MI + Veh, n = 8, MI + T3, n = 8. One-way ANOVA, multiple group comparisons using Tukey’s analysis. *p < 0.05 vs Sham, #p < 0.05 vs MI + Veh